News ArticleAurobindo Pharma Declares Rs. 7 Interim Dividend, Reports Q2 FY2026 Earnings, and Approves Subsidiary Merger
Board approves unaudited Q2 and half-year results, sets November 11 as record date for dividend, and greenlights merger of wholly owned subsidiaries
Aurobindo Pharma announced its unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2026, declared an interim dividend of Rs. 7 per share, and approved a merger scheme for its wholly owned subsidiaries, along with internal restructuring approvals.
Aurobindo Pharma Limited
Financial Results
Aurobindo Pharma Limited announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with approval of an interim dividend of Rs. 7.00 per equity share. The company also approved a merger scheme for two wholly owned subsidiaries and internal ownership restructuring of its Russian subsidiary.
The Board of Directors approved the standalone and consolidated financial results as per Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with detailed limited review reports provided by statutory auditors.
An interim dividend of 700% or Rs. 7.00 per equity share (face value Re. 1 each) was declared, with November 11, 2026 set as the record date. The dividend will be paid on or before November 20, 2026.
The Board sanctioned filing a Scheme of Amalgamation with the National Company Law Tribunal (NCLT), Hyderabad for the merger of Auroactive Pharma Private Limited and Apitoria Pharma Private Limited, both wholly owned subsidiaries.
Additionally, ownership of Auro Pharma LLC, Russia, is being transferred internally from Auroactive Pharma Private Limited to Auropharm Overseas Limited, both wholly owned subsidiaries.
Subject to member approval through postal ballot, the re-appointment of Mr. Mangalam Ramasubramanian Kumar as a Non-Executive Independent Director for a second five-year term beginning April 1, 2027, was also recommended.
Highlights
- Declared interim dividend of Rs. 7.00 per equity share with record date on November 11, 2026.
- Approved unaudited standalone and consolidated Q2 and half-year financial results ended September 30, 2026.
- Filed Scheme of Amalgamation for merger of two wholly owned subsidiaries with NCLT Hyderabad.
- Internal transfer of ownership of Russian subsidiary Auro Pharma LLC between wholly owned subsidiaries approved.
- Re-appointment of Independent Director for second term from April 1, 2027, recommended for member approval.
Key Data Snapshot
What happened
- Aurobindo Pharma declared an interim dividend of Rs. 7.00 per equity share for shareholders recorded on November 11, 2026.
- The Board approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
- Approval was given to file a scheme of amalgamation for merging two wholly owned subsidiaries before the National Company Law Tribunal, Hyderabad.
- Ownership of Auro Pharma LLC in Russia will be transferred between the company's wholly owned subsidiaries.
- Recommendation was made for re-appointment of an Independent Director for a further five-year term, subject to member approval through postal ballot.
Financial performance
- Standalone sales revenue for Q2 stood at Rs. 31,627.9 lakh with total revenue from operations of Rs. 31,773.3 lakh.
- Profit after tax from continuing operations was Rs. 7,235.8 lakh for the quarter.
- Half year total income was Rs. 63,215.3 lakh with profit after tax from continuing operations at Rs. 14,605.0 lakh.
- Earnings per equity share from continuing operations stood at Rs. 12.55 for Q2 and Rs. 25.33 for the half year.
Transaction details
- The scheme of amalgamation involves Auroactive Pharma Private Limited and Apitoria Pharma Private Limited, both wholly owned subsidiaries, aiming for consolidation.
- The ownership transfer of Auro Pharma LLC, Russia will occur within the wholly owned subsidiaries, from Auroactive Pharma Private Limited to Auropharm Overseas Limited.
Regulatory and governance context
- The filings are in compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
- The re-appointment of Independent Director is subject to shareholder approval through postal ballot.
Highlights
- Declared interim dividend of Rs. 7.00 per equity share with record date on November 11, 2026.
- Approved unaudited standalone and consolidated Q2 and half-year financial results ended September 30, 2026.
- Filed Scheme of Amalgamation for merger of two wholly owned subsidiaries with NCLT Hyderabad.
- Internal transfer of ownership of Russian subsidiary Auro Pharma LLC between wholly owned subsidiaries approved.
- Re-appointment of Independent Director for second term from April 1, 2027, recommended for member approval.
Disclosures
- Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Source Information
More News on Financial Results
View allLatest corporate announcements and market updates in Financial Results.
Tube Investments of India Posts Rs. 346.74 Crore Profit After Tax for Q2 2026 and Approves Rs. 83 Crore Capacity Expansion in Cold Rolled Steel
Tube Investments of India Limited reported a profit after tax of Rs. 346.74 crore for the quarter ended September 30, 2026, and approved an Rs. 83 crore capital expenditure to enhance Cold Rolled Steel Strips manufacturing capacity at its Avadi facility, expected to complete in fiscal year 2027-28.
Read Full Story
Sundaram Finance Announces Q2 and Half-Year FY2026-27 Results with Standalone PAT of ₹822.92 Crores and Consolidated PAT of ₹1,426.28 Crores
Sundaram Finance Limited released its unaudited standalone and consolidated financial results for the quarter and half-year ended 30 September 2026. The standalone profit after tax (PAT) stood at ₹822.92 crores for the quarter, while the consolidated PAT was ₹1,426.28 crores for the half-year period.
Read Full Story
Ipca Laboratories Records Rs 1,049.12 Crores Profit Before Tax and Rs 7,336.75 Crores Revenue for H1 FY27
Ipca Laboratories Limited announced its unaudited standalone financial results for Q2 and H1 FY27, reporting total income of Rs 7,336.75 crores and profit before tax of Rs 1,049.12 crores for the half year ended September 30, 2026.
Read Full Story
